AU2014236559B2 - Cholestosome vesicles for incorporation of molecules into chylomicrons - Google Patents

Cholestosome vesicles for incorporation of molecules into chylomicrons Download PDF

Info

Publication number
AU2014236559B2
AU2014236559B2 AU2014236559A AU2014236559A AU2014236559B2 AU 2014236559 B2 AU2014236559 B2 AU 2014236559B2 AU 2014236559 A AU2014236559 A AU 2014236559A AU 2014236559 A AU2014236559 A AU 2014236559A AU 2014236559 B2 AU2014236559 B2 AU 2014236559B2
Authority
AU
Australia
Prior art keywords
cells
cholestosomes
cholestosome
insulin
fitc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014236559A
Other languages
English (en)
Other versions
AU2014236559A1 (en
Inventor
Julie HUGHES
Mary P. Mccourt
Lawrence Mielnicki
Jerome J. Schentag
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581747&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014236559(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of AU2014236559A1 publication Critical patent/AU2014236559A1/en
Application granted granted Critical
Publication of AU2014236559B2 publication Critical patent/AU2014236559B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2014236559A 2013-03-14 2014-03-14 Cholestosome vesicles for incorporation of molecules into chylomicrons Active AU2014236559B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783003P 2013-03-14 2013-03-14
US61/783,003 2013-03-14
PCT/US2014/027761 WO2014152795A2 (en) 2013-03-14 2014-03-14 Cholestosome vesicles for incorporation of molecules into chylomicrons

Publications (2)

Publication Number Publication Date
AU2014236559A1 AU2014236559A1 (en) 2018-05-24
AU2014236559B2 true AU2014236559B2 (en) 2020-03-12

Family

ID=51581747

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014236559A Active AU2014236559B2 (en) 2013-03-14 2014-03-14 Cholestosome vesicles for incorporation of molecules into chylomicrons

Country Status (10)

Country Link
US (6) US9693968B2 (cg-RX-API-DMAC7.html)
EP (1) EP2970369B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016513712A (cg-RX-API-DMAC7.html)
CN (1) CN105164143B (cg-RX-API-DMAC7.html)
AU (1) AU2014236559B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015022936A2 (cg-RX-API-DMAC7.html)
CA (1) CA2905108C (cg-RX-API-DMAC7.html)
IL (1) IL241501B (cg-RX-API-DMAC7.html)
MX (1) MX384232B (cg-RX-API-DMAC7.html)
WO (1) WO2014152795A2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119782B2 (en) 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
JP2016513712A (ja) * 2013-03-14 2016-05-16 ジェローム， ジェイ． シェンターク， カイロミクロンへの分子の取り込みのためのコレストソーム小胞
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2016054399A1 (en) * 2014-10-01 2016-04-07 The Brigham And Women's Hospital, Inc. Enhancing dermal wound healing by downregulating microrna-26a
ES2574615B1 (es) * 2014-12-19 2017-07-24 Biopraxis Research Aie Nanopartícula lipídica de tobramicina
AU2016379403B2 (en) 2015-12-23 2020-03-12 The Johns Hopkins University Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions
CN105797132A (zh) * 2016-05-03 2016-07-27 滨州医学院 沙奎拉韦的医药新用途
WO2018039303A1 (en) * 2016-08-23 2018-03-01 Schentag Jerome J Cholesteryl ester vesicles loading peptides, proteins and nucleic acids into chylomicrons and body cells
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
CN107260681A (zh) * 2017-08-04 2017-10-20 济南维瑞医药科技开发有限公司 一种磷酸特地唑胺脂质体的制备方法及其应用
US12478585B2 (en) 2017-08-09 2025-11-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Micelles and vesicles for the delivery of glycopeptides
WO2019032877A1 (en) * 2017-08-09 2019-02-14 Arizona Board Of Regents On Behalf Of The University Of Arizona MICELLES AND VESICLES FOR RELEASE OF GLYCOPEPTIDES
US12078642B2 (en) * 2017-11-09 2024-09-03 The University Of Melbourne Methods for evaluating and improving cognitive function
CN109929806B (zh) * 2017-12-19 2020-05-08 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
US11911445B2 (en) 2018-01-23 2024-02-27 Gila Therapeutics, Inc. Peptide YY pharmaceutical formulations, compositions, and methods
WO2019148282A1 (en) * 2018-02-01 2019-08-08 The Royal Institution For The Advancement Of Learning/Mcgill University Formulations for improving the delivery of hydrophobic agents
MX2021013842A (es) * 2019-05-14 2022-01-18 Pharmosa Biopharm Inc Composicion farmaceutica de un farmaco de acido debil y metodos de administracion.
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
CN110638788A (zh) * 2019-10-25 2020-01-03 广州医科大学 一种能够沉默Pcsk9蛋白的siRNA、其纳米递送系统及应用
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023003506A (es) * 2020-09-25 2023-06-28 Algorithm Sciences Inc Composiciones y métodos para la administración de vasodilatadores.
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
WO2023112974A1 (ja) * 2021-12-14 2023-06-22 シード医療製薬株式会社 海藻抽出物を含む高血圧症改善剤並びに同高血圧症改善剤を含む機能性食品、医薬部外品及び医薬品
CN114470186B (zh) * 2022-02-17 2023-10-20 唐颐控股(深圳)有限公司 一种可吸入式纳米新冠疫苗的制备方法
KR20240157096A (ko) 2022-03-23 2024-10-31 나노베이션 테라퓨틱스 인크. 고 스테롤-함유 지질 나노입자
CN119837820B (zh) * 2023-12-13 2025-10-10 上海交通大学 一种基于蛋白载体的活性成分透皮递送系统及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225264A1 (en) * 2006-03-20 2007-09-27 Mccourt Mary P Drug delivery means

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
CA1335348C (en) 1988-03-04 1995-04-25 Yasuaki Ogawa Liposome composition
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1992003123A1 (en) 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
PT937456E (pt) 1998-02-23 2004-10-29 Cilag Ag Int Dispersao lipossomal de eritropoietina
KR100874798B1 (ko) 2002-04-26 2008-12-19 이인규 전사시 ｄｎａ 결합부위를 포함하는 원형의 아령형 디코이올리고뉴클레오티드
CA2752143C (en) * 2002-05-15 2014-09-23 Sutter West Bay Hospitals Delivery of nucleic acid-like compounds
JP4063822B2 (ja) 2003-04-11 2008-03-19 コリアナ・コズメティック・カンパニー・リミテッド 皮膚しわ改善及び皮膚美白の二重機能性化粧料組成物。
CA2524368A1 (en) 2003-05-02 2004-11-18 The Board Of Trustees Of The University Of Illinois Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
WO2004100928A1 (de) 2003-05-09 2004-11-25 Novosom Ag Injizierbare liposomale depots zum wirkstoffdelivery
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
WO2007021822A2 (en) 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
US20100080773A1 (en) * 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
EP2217221B1 (en) * 2007-10-17 2018-06-27 Korea Advanced Institute of Science and Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
CA2723434C (en) * 2008-05-05 2018-01-23 Oramed Ltd. Methods and compositions for oral administration of exenatide
DK2851084T3 (en) * 2008-05-22 2018-07-30 H Lundbeck As Modulation of Vps10p domain receptors for the treatment of cardiovascular disease
WO2010027498A2 (en) 2008-09-03 2010-03-11 New Science Holdings, Llc Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions
US9757346B2 (en) 2008-09-03 2017-09-12 Volant Holdings Gmbh Compositions and methods for treating insulin resistance and non-insulin dependent diabetes mellitus (type II diabetes)
JP2009143963A (ja) 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
US20130273154A1 (en) 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
SG184127A1 (en) 2010-03-19 2012-10-30 Massachusetts Inst Technology Lipid vesicle compositions and methods of use
US20110268653A1 (en) 2010-04-16 2011-11-03 The Board Of Regents Of The University Of Texas System Compositions and Methods Related to Acid Stable Lipid Nanospheres
US8355188B2 (en) 2010-07-27 2013-01-15 Foxlink Image Technology Co., Ltd. Document guiding mechanism
KR102198749B1 (ko) 2011-03-02 2021-01-06 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
JP2014519496A (ja) * 2011-05-11 2014-08-14 ナノヴァレント ファーマシューティカルズ，インコーポレイテッド Ａｌｃａｍ細胞表面受容体を標的とする細胞毒性重合リポソームナノ粒子による増強された骨肉腫の増殖抑制
US9693969B2 (en) 2012-01-02 2017-07-04 Andrew L. SKIGEN Mucous membrane active agent application
EP2830599B1 (en) 2012-03-29 2018-08-15 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
JP2016513712A (ja) * 2013-03-14 2016-05-16 ジェローム， ジェイ． シェンターク， カイロミクロンへの分子の取り込みのためのコレストソーム小胞
CN105377271A (zh) 2013-03-15 2016-03-02 全技术公司 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
WO2018039303A1 (en) 2016-08-23 2018-03-01 Schentag Jerome J Cholesteryl ester vesicles loading peptides, proteins and nucleic acids into chylomicrons and body cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070225264A1 (en) * 2006-03-20 2007-09-27 Mccourt Mary P Drug delivery means

Also Published As

Publication number Publication date
US12005146B2 (en) 2024-06-11
US12465575B2 (en) 2025-11-11
IL241501A0 (en) 2015-11-30
US11052052B2 (en) 2021-07-06
EP2970369A4 (en) 2016-10-12
MX2015011462A (es) 2016-05-31
US20220040116A1 (en) 2022-02-10
US20200069598A1 (en) 2020-03-05
US10369114B2 (en) 2019-08-06
WO2014152795A3 (en) 2014-11-27
IL241501B (en) 2020-05-31
US20180055780A1 (en) 2018-03-01
MX384232B (es) 2025-03-14
EP2970369B1 (en) 2023-11-22
US20160030361A1 (en) 2016-02-04
CA2905108A1 (en) 2014-09-25
US11633364B2 (en) 2023-04-25
CN105164143A (zh) 2015-12-16
JP6688408B2 (ja) 2020-04-28
CA2905108C (en) 2021-12-07
US20240398719A1 (en) 2024-12-05
AU2014236559A1 (en) 2018-05-24
HK1212354A1 (en) 2016-06-10
CN105164143B (zh) 2019-02-19
US20230277471A1 (en) 2023-09-07
US9693968B2 (en) 2017-07-04
WO2014152795A2 (en) 2014-09-25
BR112015022936A2 (pt) 2017-07-18
EP2970369A2 (en) 2016-01-20
JP2016513712A (ja) 2016-05-16
JP2019070031A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
US12465575B2 (en) Methods of treatment using cholestosome vesicles for incorporation of molecules into chylomicrons
EP2135600B1 (en) Targeting agent for cancer cell or cancer-associated fibroblast
US20230240997A1 (en) Method of treating cancer
JP2019518040A (ja) 腫瘍に対して標的化されるナノキャリアの抗体媒介性自触反応的送達
JP2018527342A (ja) 組成物
Fan et al. Lipid-based nanoparticles for cancer immunotherapy
US11344629B2 (en) Active targeting of cells by monosized protocells
JP7357629B2 (ja) 治療用ナノバイオロジー組成物での訓練された免疫の阻害
EP4337197A1 (en) Pharmaceutical compositions for treating neurological conditions
HK1212354B (en) Cholestosome vesicles for incorporation of molecules into chylomicrons
JP2010235564A (ja) フコシル化糖鎖産生細胞用物質送達担体
JP5871247B2 (ja) フコシル化糖鎖産生細胞用物質送達担体
Guo et al. Functional shell engineering of bioactive wheat-seedling nanovesicles with chitosan derivatives for synergistic metabolic therapy via enhanced oral delivery
Amiji et al. Therapeutic nanomedicine: Polymeric nanosystems for drug and gene delivery

Legal Events

Date Code Title Description
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 14 OCT 2015 TO 14 FEB 2018 IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 14 FEB 2018

FGA Letters patent sealed or granted (standard patent)